HLX85 / Shanghai Henlius Biotech, Fosun Pharma - LARVOL DELTA

Development of a first-in-class camptothecin-based antibody-drug conjugate targeting ALPP/ALPPL2 with potent antitumor activity and excellent tolerability (AACR 2026) - "ALPP/ALPPL2-ADC is a promising therapeutic candidate for solid tumors, particularly gynecologic cancers. As a first-in-class camptothecin-based ADC targeting ALPP/ALPPL2, it combines high antibody specificity with robust antitumor efficacy and favorable tolerability, supporting advancement into clinical development."

ADC • Gastric Adenocarcinoma • Gastric Cancer • Gynecologic Cancers • Oncology • Pancreatic Adenocarcinoma • Solid Tumor • ALPP

Exploiting biparatopic binding to deliver novel, differentiated ALPP/ALPPL2 targeting protein drug conjugates (AACR 2024) - "Additionally, in multiple CDX models, lead biparatopic PDCs demonstrate improved efficacy over an ALPP/ALPPL2 ADC both on a mg/kg and on a payload equivalents basis, in both single dose and multi-dose studies, providing complete regressions. Based on this excellent efficacy profile and favourable developability characteristics, preclinical development activities have been initiated."

Late-breaking abstract • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPP

At this year’s AACR conference, Henlius will showcase seven early-stage innovative assets with first-in-class (FIC) or best-in-class (BIC) potential. (Henlius Press Release) - "These include...multiple novel ADC candidates developed based on proprietary platform Hanjugator, including the EGFR×cMET bispecific ADC HLX48, HER2 biparatopic ADC HLX49, ADAM9 ADC HLX402, and ALPP/ALPPL2 ADC HLX85."

Preclinical • Oncology